The primary objective of this study is to determine whether primary PC is non-inferior to specialty PC for improving quality of life (QOL) in patients with AML.
In this study we want to find out the safest dose of the oral drug revumenib to give young children with KMT2A acute lymphoblastic leukemia that has come back or not responded to other treatment. We want to see if this treatment in combination with chemotherapy improves the health and survival of children with this type of cancer.
To determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and young adults (CAYA) with high-risk T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy).
Although non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK), c-ros oncogene 1(ROS1), and ret proto-oncogene (RET) gene fusions initially respond well to tyrosine kinase inhibitor (TKI) therapies, acquired resistance is inevitable. In many of these cases, increased activation of the erythroblastic leukemia viral oncogene homologue (ERBB) or cMet pathways appears to be...
The primary objective of this Phase I open-label study is to assess the safety and tolerability of CD19x22 CAR T cells in pediatric patients with R/R B-ALL.
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.
This study will test if one dose of psilocybin, given with talk therapy, can safely help people with advanced cancer feel less anxious, less depressed, and improve quality of life. We will compare it to a placebo (inactive medicine) called niacin given with the same kind of talk therapy.